Spectral Medical Announces Publication of EDEN Observational Study
Globenewswire· 2025-09-16 11:30
New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient GroupTORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today highlighted newly published findings in Critical Care Explorations that define endotoxic septic shock (“ESS”) as a distinct and deadly form of septic shock. The prospective, ...
Humanoid Global Announces Commitment to a Strategic Investment in Agility Robotics, Developers of One of the World’s First Commercially Deployed Humanoid Robot
Globenewswire· 2025-09-16 11:30
– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –Vancouver, BC & Salem, Oregon, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCPK:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, is pleased to announce that it has committed to an indirect strategic investment of US$ 145,000 into Agil ...
DeFi Technologies Invests in Continental Stablecoin Inc., Backers of cNGN, to Accelerate Regulated Stablecoin Adoption Across Africa
Prnewswire· 2025-09-16 11:30
Accessibility StatementSkip Navigation TORONTO, Sept. 16, 2025 /PRNewswire/ - DeFi Technologies Inc. (the "Company" or "DeFi Technologies") (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial technology company closing the gap between traditional capital markets and decentralized finance, is pleased to announce a strategic investment in Continental Stablecoin Inc. ("CSI"), driving development and advocacy for local-currency stablecoins in Africa, notably including the developers of Nigeria's premier regul ...
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
Globenewswire· 2025-09-16 11:30
-- Upsized Series A Financing Brings Total Amount Raised to $133 Million -- -- GAD Affects 3.1% of U.S. Adult Population; Minority of Patients Receive Treatment -- -- Reunion Expects to Initiate RECLAIM Phase 2 Trial Evaluating RE104 for GAD in 1Q 2026 -- MORRISTOWN, N.J., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psyched ...
Alset AI Announces Technology Veteran Kurtis Krack Appointed President of Lyken.AI to Drive Growth
Accessnewswire· 2025-09-16 11:30
Formerly at Denvr Dataworks Corp., OnX, and EMC/Dell, Krack Brings Deep Expertise in Platform Expansion, Revenue Generation, and Large-scale Infrastructure Solutions VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / September 16, 2025 / Alset AI Ventures Inc. (TSXV:GPUS)(OTC PINK:GPUSF)(FSE:1R60)(WKN:A3ESVQ) ("Alset AI" or the "Company") an artificial intelligence ("AI") venture company advancing innovation through strategic investment and cloud computing solutions is pleased to announce the appointment of Ku ...
Generation Uranium Announces European Road Show With High Net Worth Investors
Thenewswire· 2025-09-16 11:30
Vancouver, BC – September 16, 2025 – TheNewswire - Generation Uranium Inc. (TSXV: GEN) (OTCQB: GENRF) (FSE: W85) (the “Company” or “Generation”) is pleased to announce that it has commenced a three-day European road show, presenting to over 75 high-net-worth investors and institutional funds at Frankfurt, Munich, and Zurich.The road show reflects growing international interest in Generation and its 100%-owned Yath Uranium Project in Nunavut. Management expects these presentations to significantly broaden sh ...
Glow Lifetech Expands MOD and .decimal brands in Saskatchewan Market, Advancing National Growth Strategy
Newsfile· 2025-09-16 11:30
Glow Lifetech Expands MOD and .decimal brands in Saskatchewan Market, Advancing National Growth StrategySeptember 16, 2025 7:30 AM EDT | Source: Glow Lifetech Corp.Toronto, Ontario--(Newsfile Corp. - September 16, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the expansion of its MOD™ and .decimal™ brands in Saskatchewan, marking another important step forward in the Company's national growth strategy.Expanding National Footp ...
ESA's Skimsat VLEO Mission Moves forward with Redwire Primeship in Cooperation with Thales Alenia Space
Businesswire· 2025-09-16 11:30
PARIS--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has reached an agreement with Thales Alenia Space, a joint venture between Thales (67%) and Leonardo (33%), with the support of the European Space Agency (ESA) to become the prime contractor for Skimsat, whose preliminary study was coordinated under Thales Alenia Space's responsibility. Skimsat is an ESA technology demonstration mission for a small satellit. ...
Humanoid Global Announces Commitment to a Strategic Investment in Agility Robotics, Developers of One of the World's First Commercially Deployed Humanoid Robot
Globenewswire· 2025-09-16 11:30
Vancouver, BC & Salem, Oregon, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCPK:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, is pleased to announce that it has committed to an indirect strategic investment of US$ 145,000 into Agility Robotics, Inc. (“Agility Robotics”), via a fund that holds shares of Agility ...
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
Globenewswire· 2025-09-16 11:30
MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of a new article in a peer-reviewed journal Biomolecules, which describes the pharmacokinetic (PK) profile of a new crystal form of buntanetap and compares it to the old form across several studie ...